Impact of early tumour shrinkage (ETS) on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line treatment in three randomised panitumumab trials: An exploratory study-level meta-analysis

被引：0
|
作者：
Karthaus, M. [1 ]
Rivera, F. [2 ]
Valladares-Ayerbes, M. [3 ]
Gallego, J. [4 ]
Koukakis, R. [5 ]
Demonty, G. [6 ]
Douillard, J. -Y [7 ]
机构：
[1] Stadt Klinikum Munchen, Klinikum Neuperlach, Munich, Germany
[2] Hosp Univ Marques de Valdecilla, Santander, Spain
[3] Virgen del Rocio Hosp, Seville, Spain
[4] Hosp Gen Univ Elche, Elche, Spain
[5] Amgen Ltd, Uxbridge, Middx, England
[6] Amgen Europe GmbH, Zug, Switzerland
[7] Inst Cancerol Ouest ICO Rene Gauducheau, St Herblain, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P302
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials
    Rivera, F.
    Karthaus, M.
    Valladares-Ayerbes, M.
    Gallego, J.
    Koukakis, R.
    Demonty, G.
    Douillard, J. -Y.
    ANNALS OF ONCOLOGY, 2016, 27 : 114 - 114
  • [2] Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
    Taieb, Julien
    Rivera, Fernando
    Siena, Salvatore
    Karthaus, Meinolf
    Valladares-Ayerbes, Manuel
    Gallego, Javier
    Geissler, Michael
    Koukakis, Reija
    Demonty, Gaston
    Peeters, Marc
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (02) : 321 - 335
  • [3] Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
    Julien Taieb
    Fernando Rivera
    Salvatore Siena
    Meinolf Karthaus
    Manuel Valladares-Ayerbes
    Javier Gallego
    Michael Geissler
    Reija Koukakis
    Gaston Demonty
    Marc Peeters
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 321 - 335
  • [4] Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
    Julien Taieb
    Fernando Rivera
    Salvatore Siena
    Meinolf Karthaus
    Manuel Valladares-Ayerbes
    Javier Gallego
    Michael Geissler
    Reija Koukakis
    Gaston Demonty
    Marc Peeters
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 795 - 797
  • [5] Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type (WT) metastatic colorectal cancer (mCRC): a retrospective analysis of three panitumumab (pmab) studies
    Geissler, M.
    Taieb, J.
    Rivera, F.
    Karthaus, M.
    Wilson, R.
    Loupakis, F.
    Price, T.
    Tracy, M.
    Burdon, P.
    Peeters, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 120 - 122
  • [6] Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials (vol 144, pg 321, 2018)
    Taieb, Julien
    Rivera, Fernando
    Siena, Salvatore
    Karthaus, Meinolf
    Valladares-Ayerbes, Manuel
    Gallego, Javier
    Geissler, Michael
    Koukakis, Reija
    Demonty, Gaston
    Peeters, Marc
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (04) : 795 - 797
  • [7] Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies
    Taieb, J.
    Geissler, M.
    Rivera, F.
    Karthaus, M.
    Wilson, R.
    Loupakis, F.
    Price, T.
    Tracy, M.
    Burdon, P.
    Peeters, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 96 - 96
  • [8] Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
    Claus-Henning Köhne
    Meinolf Karthaus
    Laurent Mineur
    Josef Thaler
    Marc Van den Eynde
    Javier Gallego
    Reija Koukakis
    Marloes Berkhout
    Ralf-Dieter Hofheinz
    Drugs in R&D, 2019, 19 : 267 - 275
  • [9] Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
    Koehne, Claus-Henning
    Karthaus, Meinolf
    Mineur, Laurent
    Thaler, Josef
    Van den Eynde, Marc
    Gallego, Javier
    Koukakis, Reija
    Berkhout, Marloes
    Hofheinz, Ralf-Dieter
    DRUGS IN R&D, 2019, 19 (03) : 267 - 275
  • [10] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY TRIALS IN FIRST-LINE RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Jarrett, J.
    Weijers, L.
    Hnoosh, A.
    Harty, G.
    von Hohnhorst, P.
    VALUE IN HEALTH, 2014, 17 (07) : A617 - A617
12345